Studies have reported that increased expression and overexpression of Grb2 relate to poor prognosis in patients with gastric cancer and lymph node metastasis and poor survival in esophageal cancer patients, respectively [64,65]. This evidence concerns the gene GRB2 and metastatic malignant neoplasm in the lymph nodes.